Table 5.

Characteristics of patients treated with hepatic arterial infusion of cisplatin and IV liposomal doxorubicin with stable disease or better and their best response

Patient No.	Age/Sex	PS	Cisplatin/Doxil (mg/m2)	No. of prior Rx	No. of cycles	Type of cancer	Response	%	Reason off-protocol Comments
1	55/F	0	100/20	9	5	Breasta	SD	−10	Withdrew consent b/c of fatigue, neuropathy
5	61/M	1	100/25	1	4	Ocular melanoma	PR	−38	PD
10	27/M	0	100/30	0	4	Ocular melanoma	SD	−15	Lost to follow-up
17	63/F	1	100/35	9	4	Breast	SD	−22	Withdrew consent b/c of N/V, weight loss
22	50/F	0	125/35	11	4	Breast	PR	−42	PD
23	54/F	1	100/35	8	6	Breast	SD	−13	PD
24	51/F	1	100/35	8	4	Breast	PR	−51	Withdrew consent b/c of need for hospitalization
25	57/F	1	100/35	4	6	Breast	PR	−44	PD
28	15/F	1	100/35	3	4	Hepatocellular	SD	−5	Further assessment for resection/liver transplant
31	61/F	1	100/35	6	4+	Breast	SD	−10	N/A
32	40/F	1	100/35	5	4+	Breast	SD	−9	N/A

N/A non-applicable, PD progressive disease, PR partial response, PS performance status, SD stable disease

^aFollowing discontinuation of HAI of cisplatin and IV liposomal doxorubicin because of poor tolerance, the patient was treated with low-dose vinorelbine and trastuzumab every other week for 5 months. Her neuropathy worsened, and subsequently resection of liver metastases was attempted, but the tumor involved major vascular structures, and therefore resection of metastases was not possible